<DOC>
	<DOCNO>NCT02971891</DOCNO>
	<brief_summary>evaluate efficacy safety six ( 6 ) week daily application Furosemide Topical Gel 0.125 % ( CLS006 ) compare vehicle subject â‰¥ 12 year age nongenital cutaneous common wart ( verruca vulgaris ) .</brief_summary>
	<brief_title>A Phase 3 Study Evaluate Efficacy Safety CLS006 Versus Vehicle Subjects 12 Years Age Older With Cutaneous Common Warts</brief_title>
	<detailed_description />
	<mesh_term>Warts</mesh_term>
	<mesh_term>Furosemide</mesh_term>
	<criteria>Subjects 1 6 clearly identifiable common wart locate hand foot limb , and/or trunk Each wart must 3 10 mm long dimension ( diameter ) epidermal plane skin , Each wart must present least 4 week , Plantar , facial , subungual , common wart region preexist inflammatory condition exclude . In addition , wart ( e.g. , flat , genital ) exclude . Male female subject 12 year age old Females childbearing potential use highly effective form birth control .females nonchildbearing potential Negative inoffice urine pregnancy test Screening Baseline Subjects free clinically significant dermatologic disorder treatment area Subjects free clinically significant systemic condition interfere study assessment increase risk AEs Subjects willing refrain use topical product treatment area , prohibit medication duration study Subjects use wart treatments/therapies , prescription overthecounter , follow : Salicylic acid , cantharidin , sinecatechins ( VeregenTM ) , simple occlusion ( e.g. , duct tape ) , and/or overthecounter wartremoving product treatment area within 4 week Baseline Visit . Cryotherapy ( e.g. , treatment liquid nitrogen ) , carbon dioxide , electrodessication , laser , surgery , form mechanical destruction ( e.g. , emery board , clipper , debriders , etc . ) treatment area within 8 week Baseline Visit . Treatment immunotherapy ( DPCP , DNCB ) , imiquimod , 5fluorouracil , bleomycin , podophyllin wart immunotherapy treatment ( e.g. , Candida antigen ) design stimulate immune response within 12 week Baseline Visit . Subjects immunocompromised . Subjects take , within 30 day prior enrollment , require treatment systemic immunosuppressive immunomodulatory medication ( include oral parenteral corticosteroid ) course study Subjects require ongoing treatment oral injectable furosemide Subjects use investigational drug/device within 30 day Baseline visit Subjects know sensitivity investigational product ingredient include furosemide ( sulfonamide ) . Subjects clinically significant abnormality cardiovascular , hepatic renal system . Subjects clinically relevant/significant abnormal laboratory result , vital sign , ECG , and/or physical finding Screening and/or Baseline Subjects chronic medical condition clinically significant abnormal physical laboratory finding ( ) may require use prohibited medication/treatment . Subjects currently abuse alcohol drug history chronic alcohol drug abuse within past year .</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>